Clinical Trial Update: ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI [Phase 2]

View source ↗

Summary

A Phase 2 trial assessing rechallenge with immune checkpoint inhibitors in advanced Non-small cell lung cancer patients who previously had a long-term response …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: RECRUITING